Paolo Rocco

Dr. Paolo Rocco

Università degli Studi di Milano, Milan, Italy
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2017 in Planta Medica
Verified
Journal Article
Closed access
PDF file
ACAntonella Casiraghi
Antonella Casiraghi
GRGabriella Roda
Gabriella Roda
ECEleonora Casagni
Eleonora Casagni
CCCecilia Cristina
Cecilia Cristina
UMUmberto Musazzi
Umberto Musazzi
VGVeniero Gambaro
Veniero Gambaro
Recently, an increasing number of pharmacists had to supply medicinal products based on Cannabis sativa L. (Cannabaceae), prescribed by physicians to individual patients. Cannabis olive oil preparation is the first choice as a concentrated extract of cannabinoids, even though standardized operative conditions for obtaining it are still not available. In this work, the impact of temperature and extraction time on the concentration of active principles was studied to harmonize the different compounding methods, optimize the extraction process, and reduce the variability among preparations. Moreover, starting from the cannabis inflorescence, the effect of temperature on tetrahydrocannabinolic acid decarboxylation was evaluated. For the analysis, a GC/MS method, as suggested by the Italian Ministry of Health, and a GC/flame ionization detection method were developed, validated, and compared.

1 January 2012 in Drug Discovery Today
Verified
Journal Article
Closed access
PMPaola Minghetti
Paola Minghetti
PRPaolo Rocco
Paolo Rocco
Francesco CilurzoFrancesco Cilurzo
Francesco Cilurzo
LVLucia Del Vecchio
Lucia Del Vecchio
Francesco LocatelliFrancesco Locatelli
Francesco Locatelli

6 June 2022 in Robotics and Computer-Integrated Manufacturing
Verified
Journal Article
Closed access
NLNiccolò Lucci
Niccolò Lucci
AMAndrea Monguzzi
Andrea Monguzzi
AZAndrea Maria Zanchettin
Andrea Maria Zanchettin
PRPaolo Rocco
Paolo Rocco

13 December 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Lucia Del VecchioLucia Del Vecchio
Lucia Del Vecchio
MAMarco Allinovi
Marco Allinovi
PRPaolo Rocco
Paolo Rocco
Bruno BRANDOBruno BRANDO
Bruno BRANDO
Rituximab is a chimeric anti-CD20 monoclonal antibody. It acts mainly through complement-dependent cytotoxicity on B cells expressing the CD20 marker. In this review, we analyse the efficacy and possible pitfalls of rituximab to treat nephrotic syndromes by taking into account pharmacological considerations and CD19 marker testing utility. Despite the fact that the drug has been in use for years, efficacy and treatment schedules in adults with nephrotic syndrome are still a matter of debate. Clinical trials have proven the efficacy and safety of rituximab in idiopathic membranous nephropathy. Data from observational studies also showed the efficacy of rituximab in minimal change disease and focal segmental glomerulosclerosis. Rituximab use is now widely recommended by new Kidney Disease Improved Outcome (KDIGO) guidelines in membranous nephropathy and in frequent-relapsing, steroid-dependent minimal change disease or focal segmental glomerulosclerosis. However, rituximab response has a large interindividual variability. One reason could be that rituximab is lost in the urine at a higher extent in patients with nonselective nephrotic proteinuria, exposing patients to different rituximab plasma levels. Moreover, the association between CD19+ levels and clinical response or relapses is not always present, making the use of this marker in clinical practice complex. High resolution flow cytometry has increased the capability of detecting residual CD19+ B cells. Moreover, it can identify specific B-cell subsets (including IgG-switched memory B cells), which can repopulate at different rates. Its wider use could become a useful tool for better understanding reasons of rituximab failure or avoiding unnecessary retreatments.

9 June 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Silvia FranzèSilvia Franzè
Silvia Franzè
FSFrancesca Selmin
Francesca Selmin
PRPaolo Rocco
Paolo Rocco
GCGiuseppe Colombo
Giuseppe Colombo
ACAntonella Casiraghi
Antonella Casiraghi
Francesco CilurzoFrancesco Cilurzo
Francesco Cilurzo
The freeze-drying of complex formulations, such as liposomes, is challenging, particularly if dispersions contain residual organic solvents. This work aimed to investigate the effects of possible protectants, namely sucrose, trehalose and/or poly(vinyl pyrrolidone) (PVP), on the main features of the dried product using a 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)-based liposomal dispersion prepared by ethanol injection and containing ethanol up to 6%, as a model. The interactions among vesicles and protectants were preliminary screened by Molecular Dynamics (MD) simulations, which have been proved useful in rationalizing the selection of protectant(s). The freeze-drying protocol was based on calorimetric results. Overall data suggested a stronger cryo-protectant effect of trehalose, compared with sucrose, due to stronger interactions with the DPPC bilayer and the formation of highly ordered clusters around the lipids. The effect further improved in the presence of PVP. Differently from the other tested protectants, the selected trehalose/PVP combination allows to preserve liposome size, even in the presence of 6% ethanol, as demonstrated by Nanoparticle Tracking Analysis (NTA). Nevertheless, it should be also underlined that cakes blew out at an ethanol concentration higher than 1% v/v, probably due to the poor cohesion within the cake and solvent vapour pressure upon sublimation.

3 August 2010 in Nephron Clinical Practice
Verified
Journal Article
Open access
PDF file
PMPaola Minghetti
Paola Minghetti
PRPaolo Rocco
Paolo Rocco
LVLucia Del Vecchio
Lucia Del Vecchio
Francesco LocatelliFrancesco Locatelli
Francesco Locatelli
The patent expirations for many biotechnological medicines have prompted the development of copies of biological medicinal products. Unlike generics, biosimilars are similar but not identical to their reference product, because their chemical characteristics are directly related to the manufacturing process which cannot be precisely duplicated. The regulatory policy for biosimilars is complex and in Europe it is regulated mainly by guidelines issued by the European Medicines Agency (EMEA); additional product-class specific guidelines have been developed as in the case of recombinant human erythropoietin (rHuEPO). In 2008, the experience gained with this drug has prompted the development of a new guideline, currently in draft. In this review we critically discuss aspects related to EMEA guidelines, particularly focusing on rHuEPO.